Medical Properties Trust (MPW) Stock on December 11, 2025: Dividend Hike, Options Surge and a High‑Risk Recovery Story

Updated: December 11, 2025

Medical Properties Trust (NYSE: MPW) has staged one of the more dramatic “from disaster to maybe-OK” turnarounds in the REIT world — and as of December 11, 2025, that story just got more complicated.

The hospital-focused real estate investment trust has:

• Raised its dividend by 12%
• Authorized a $150 million share repurchase program
• Reported another GAAP net loss weighed down by tenant-related impairments
• Attracted unusually heavy options trading and stubbornly high short interest
• Become the subject of sharply divided analyst and blogger opinions

Here’s a structured look at where MPW stands today, what the latest news actually means, and how current forecasts frame the bull–bear debate.

1. MPW Stock Today: Price, Performance and Volatility

As of late trading on December 11, 2025, Medical Properties Trust stock is changing hands at about $5.08 per share, down around 7.9% on the day after opening at $5.43 and touching an intraday high of $5.50.

Over a longer horizon, the picture looks very different:

• From roughly December 2024 to early December 2025, MPW has climbed from about $3.95 to the mid‑$5s, a gain of close to 39%, comfortably beating the broader market over the same period. ^[1]
• Despite that rebound, Simply Wall St notes the shares are still down more than 60% over five years, underscoring how deep the prior drawdown was. ^[2]

MPW remains a highly volatile stock. MarketBeat data show:

• A 52‑week range roughly from the low‑$3s to mid‑$6s
• A beta above 1, signalling bigger swings than the broader market ^[3]

Short interest is still elevated. Finimize and other data providers estimate that roughly 25–31% of the free float is sold short, placing MPW among the more heavily shorted REITs on the market. ^[4]

That’s the setup: a high‑yield, high‑volatility turnaround name with plenty of skeptics still leaning against it.

2. A 12% Dividend Hike and New Buyback: Confidence or Gamble?

The new payout

On November 17, 2025, Medical Properties Trust’s board approved a 12% increase in its regular quarterly dividend, from $0.08 to $0.09 per share. The dividend is payable January 8, 2026 to shareholders of record as of December 11, 2025 — today’s ex‑dividend date. ^[5]

At the current share price, that translates to an annualized dividend of $0.36, implying a forward yield in the mid‑6% range. ^[6]

Management framed the hike as a signal of confidence in future cash flows. The company’s press release tied the larger dividend to:

• Improving portfolio cash rents
• Ongoing progress recycling capital from weaker assets
• The flexibility created by recent refinancing activity ^[7]

The $150 million share repurchase authorization

The dividend news came alongside confirmation of a $150 million common stock repurchase program, first announced with MPW’s third‑quarter results. Management explicitly suggested that buying back MPW shares could be “one of the best investments” the company can make given its view of intrinsic value. ^[8]

That’s an unusually aggressive posture for a REIT that:

• Is still reporting GAAP net losses
• Carries a heavily leveraged balance sheet
• Continues to work through tenant restructurings and asset sales ^[9]

How outside analysts read the raise

Recent coverage has generally interpreted the dividend hike as a turning‑point signal, but with caveats:

• A Seeking Alpha note summarised across several feeds describes the raise as “foretelling stability”, upgrading the stock to a hold rating on the view that FFO (funds from operations) and payout metrics are now on a firmer footing, even if Q3 FFO and EPS missed expectations. ^[10]
• Zacks and other outlets have echoed the “rewarding investors with a 12–12.5% raise” framing, while stressing that MPW remains a high‑yield, high‑risk income play, not a sleepy bond‑proxy REIT. ^[11]

In short: the dividend move leans bullish, but it doesn’t erase the underlying risks.

3. Q3 2025 Results: Losses on Paper, Cash Flow in Focus

MPW reported its third‑quarter 2025 results on October 30, 2025. The headline numbers were messy but directionally less grim than the prior year. ^[12]

Key points:

• Net loss:
  • –$78 million, or –$0.13 per share, versus a far larger loss of –$801 million (–$1.34 per share) a year earlier.
  • The loss was driven largely by about $82 million in impairment charges tied to restructuring at troubled tenant Prospect Medical. ^[13]
• Normalized Funds From Operations (NFFO):
  • $77 million, or $0.13 per share, versus $94 million ($0.16 per share) in Q3 2024 — down year over year, but still positive. ^[14]
• Revenue:
  • Around $237.5 million, up about 5.2% year over year but slightly below or just around some analyst expectations. ^[15]

The quarter also gave a clearer view into the cash-rent ramp‑up from newly re‑tenanted properties:

• Cash collections from new tenants increased from $11 million in Q2 to $16 million in Q3, and management guided to roughly $22 million for Q4 2025 (excluding some rent collected just after quarter‑end). ^[16]

Management reiterated a target of more than $1 billion in pro‑rata annualized cash rent by the end of 2026, contingent on successful tenant transitions and regulatory approvals. ^[17]

The message: GAAP earnings remain negative, but the path of recurring cash rents is improving — if the plan holds.

4. Tenant Cleanup and the Prospect / Yale / NOR Triangle

The weakest link in MPW’s story has long been its exposure to financially stressed hospital operators, notably Prospect Medical and formerly Steward Health Care. 2025 has been about containing that damage.

Yale settlement and DIP loan

In a September 29, 2025 portfolio update, MPW detailed a settlement with Yale New Haven Health System and Prospect. Yale agreed to pay $45 million to Prospect, with proceeds expected to substantially reduce — and ultimately fully repay — MPW’s debtor‑in‑possession (DIP) loan to Prospect when combined with asset sale proceeds. ^[18]

The same update noted:

• MPW sold two Arizona facilities for about $50 million to their current operator
• After the Yale settlement, Connecticut hospital sales and other previously announced California transactions, MPW expects full repayment of its recent ~$105 million DIP loan, with only a conditional $30 million commitment remaining. ^[19]

NOR Healthcare lease

Prospect’s California operations are expected to transition to NOR Healthcare Systems Corp., with MPW agreeing in principle to a new lease structure:

• Stabilized annual cash rent of about $45 million,
• 50% of that rent during the first six months post‑closing,
• Full rent after twelve months, subject to regulatory approvals. ^[20]

Simply Wall St’s recent liquidity‑focused piece highlights this NOR lease as a key driver of future rent coverage, while warning that tenant concentration risk remains meaningful even after these moves. ^[21]

Portfolio snapshot

As of September 30, 2025, MPW reported:

• Total assets of about $14.9 billion, including:
  • ~$9.0 billion of general acute care hospitals
  • ~$2.5 billion of behavioral health facilities
  • ~$1.6 billion of post‑acute facilities
• 388 properties and around 39,000 licensed beds across the U.S. and eight additional countries. ^[22]

The big picture: MPW is slowly swapping distressed tenants and low‑yield assets for more stable operators and cash — but the process is still underway, and leverage remains high.

5. What Current Research and Valuation Models Say

5.1. Simply Wall St: “Value or value trap?”

A fresh December 11, 2025 analysis from Simply Wall St asks whether the recent rebound makes Medical Properties Trust a bargain or a trap. Their work highlights:

• MPW shares are up over 40% in the past year, yet still deeply negative over three and five years. ^[23]
• A proprietary discounted cash‑flow (DCF) model pegs fair value at about $7.2 per share, implying roughly 24% upside from the mid‑$5s. ^[24]
• On a price‑to‑sales multiple, MPW trades around 3.3× revenue, versus roughly 6.4× for the broader health‑care REIT group and more than 7× for selected peers, suggesting a discount on sales‑based metrics. ^[25]

However, a separate December 10 Simply Wall St “narrative” piece notes that the most popular fair‑value scenario on their platform sits closer to $5.14 per share, mildly below recent prices, and that sell‑side analysts’ own consensus price target is around $4.86 (range: $4 to $6). ^[26]

In other words: even within a single research platform, some models scream “undervalued,” while other assumptions show modest overvaluation.

5.2. Liquidity focus and fair value near $5

An earlier November 30 Simply Wall St update framed MPW’s story around liquidity management:

• The company has no remaining debt maturities in 2025 after refinancing activities.
• The $0.09 dividend was interpreted as a sign of stable income policy, not a major shift in the investment thesis.
• A scenario‑based forecast sees revenue trending toward about $1.1 billion and positive earnings by 2028, but still assigns a fair value estimate of $5.07 per share, implying downside from recent trading levels. ^[27]

That reinforces the idea that valuation is highly assumption‑sensitive for MPW.

5.3. Yahoo Finance and valuation models

A valuation piece syndicated via Yahoo Finance on December 2 notes that, with MPW trading around $5.62 at the time, a widely‑followed fair‑value model placed intrinsic value near $5.07, suggesting the stock was roughly 11% overvalued on that methodology. ^[28]

Taken together with the Simply Wall St narratives, investors are faced with a wide band of “fair value” estimates — from about $4 on the bearish side to more than $7 on optimistic DCF‑driven views.

5.4. Analyst ratings and price targets

Across several aggregators, analyst sentiment is cautious:

• MarketScreener and MarketWatch both show an average rating around “Hold” and an average 12‑month price target near $5.1, very close to where the stock trades today. ^[29]
• MarketBeat cites a “Reduce” consensus rating with an average target of $5.63, based on recent updates, including a Wells Fargo target of $5 and several outright sell stances. ^[30]
• Forecast compilers such as Investing.com, Fintel and StockAnalysis report average price targets generally between $5.1 and $5.5, with lows around $4.0–4.5 and highs in the $6–9 range. ^[31]

Net message: the median Wall Street view is that MPW is roughly fairly valued around current levels, with modest upside and material downside risk, rather than a consensus “deep value” opportunity.

6. Earnings and FFO Forecasts: Slowly Climbing Out of the Hole

Looking ahead, the key debate is whether MPW can grow its cash earnings enough to justify the dividend and further re‑rating.

EPS / FFO consensus

Different data providers quote slightly different figures depending on whether they track EPS or REIT‑style FFO, but the direction is broadly similar:

• Nasdaq and Barchart show normalized EPS/FFO expectations of roughly $0.55–0.57 in 2025, rising toward $0.68–0.72 in 2026. ^[32]
• WallStreetZen, which focuses on GAAP EPS, notes MPW’s current EPS at about –$1.18, with 2025 EPS still negative (around –$0.26 in the consensus), but turning positive in 2026 and gradually improving through 2027. ^[33]
• Seeking Alpha’s earnings‑estimate page similarly lists 2025 revenue around $950 million and a FFO recovery path that aligns with the dividend hike being mathematically sustainable if management hits its targets. ^[34]

The gap between GAAP EPS and FFO matters:

• GAAP results remain heavily affected by non‑cash impairments tied to troubled tenants and asset sales.
• The dividend is more directly linked to recurring cash rents and FFO, which analysts expect to recover gradually, though not explosively.

That’s why some analysts can argue the dividend is adequately covered even while the payout ratio on GAAP earnings looks nonsensical.

7. Market Sentiment: Options Surge and Heavy Short Interest

On December 10, 2025, MPW became the focus of an unusual burst of derivatives activity:

• Traders bought about 169,000 call options in a single day — more than 500% above the typical daily call volume of roughly 28,000 contracts.
• The stock rose about 1.2% to $5.52 during that session. ^[35]

The same MarketBeat report highlighted:

• A debt‑to‑equity ratio around 2.1,
• A still‑negative net margin and return on equity,
• A consensus expectation that MPW will post positive earnings per share for the full year, despite the latest quarterly miss. ^[36]

Layer that on top of short interest in the high‑20s to low‑30s percent of float, and you have the classic ingredients for occasional sharp squeezes — both to the upside and downside — as sentiment flips between optimism on the recovery and fear of renewed tenant stress. ^[37]

8. Key Risks That Still Matter

Despite the share price recovery and dividend raise, MPW is not a low‑risk income vehicle. Recent analyses and company disclosures converge on several persistent risk factors:

1. High leverage
   Net debt remains substantial; some estimates place MPW’s net debt‑to‑EBITDA well into the teens, far above typical REIT comfort zones. This makes the company sensitive to interest‑rate levels and refinancing conditions, even after the removal of near‑term 2025 maturities. ^[38]
2. Tenant concentration and credit quality
   A relatively small number of major operators still account for a large share of rent. While the NOR and Yale transactions reduce acute stress around Prospect, the broader tenant‑credit picture is not yet boring and stable, and further impairments are possible if operating performance stumbles. ^[39]
3. Thin operating margins
   Finimize notes that MPW’s operating margin is only a few percentage points, far below market averages. Add in non‑cash charges, and GAAP earnings remain fragile. ^[40]
4. Regulatory and reimbursement risk
   Hospital profitability depends heavily on government and insurer reimbursement patterns. Changes in Medicare, Medicaid or national health‑system policies in the U.S. and Europe could ripple back into rent‑coverage ratios for MPW’s tenants. ^[41]
5. Valuation uncertainty and sentiment swings
   The range of “fair value” estimates — from about $4 to $7+ — reflects genuine uncertainty, not just noisy models. With so much short interest and such a wide spread in analyst targets, MPW’s share price is likely to stay emotionally charged. ^[42]

For investors, these risks don’t necessarily rule MPW out — but they demand a higher tolerance for volatility and the possibility that the turnaround thesis takes longer (and more dilution or asset sales) than hoped.

9. 2026 Outlook: How Bulls, Bears and Neutrals See MPW

Bull case

The optimistic view, reflected in some Seeking Alpha upgrades and the higher end of analyst price targets, goes roughly like this: ^[43]

• Re‑tenanting continues to work, with NOR and other operators ramping payments toward that $1 billion+ annual cash‑rent target for 2026.
• Asset sales at reasonable prices plus buybacks compound per‑share FFO growth.
• Interest‑rate pressure eases or stabilizes, making MPW’s high yield more attractive versus bonds.
• In that scenario, a share price in the high‑$5s to $7 range could be justified over time, especially if DCF‑style cash‑flow forecasts prove accurate.

Bear case

The bearish camp, which still includes some “Reiterate Sell” commentary, worries that: ^[44]

• Tenant stress may re‑emerge, forcing new impairment charges and undercutting FFO.
• High leverage constrains flexibility just as refinancing costs stay elevated.
• The dividend hike proves premature, eventually forcing another cut that would hit sentiment hard.
• In that world, MPW drifts back toward the low‑$4s or lower as equity holders re‑price the risk.

“Meh” middle

Most institutional research sits somewhere in between:

• Consensus 12‑month targets cluster in the $5.1–$5.5 band, only modestly above today’s price. ^[45]
• Forecasts assume slow improvement in FFO and a stable but not rapidly growing dividend.

This middle view essentially says: MPW might work as an income vehicle with some optionality, but it’s no longer a screaming bargain now that the stock has nearly doubled off its lows.

10. Bottom Line: Who Is MPW Really For Now?

On December 11, 2025, Medical Properties Trust sits at a crossroads:

• The worst tenant stress appears to be passing, with concrete progress on Prospect, Yale, and NOR lease transitions.
• Cash‑flow metrics are stabilizing, just enough to support a 12% dividend hike and a sizable buyback authorization.
• The balance sheet is still stretched, and valuation models disagree wildly about what the company is truly worth.
• Market sentiment is polarized, with heavy short interest on one side and aggressive call‑option buying on the other.

For conservative income investors, MPW may still feel too complex and leveraged compared with safer, more diversified REITs.

For risk‑tolerant yield hunters and turnaround specialists, MPW remains interesting precisely because sentiment and fair‑value models are so split. The stock offers a high yield, a visible (if bumpy) path to FFO recovery, and plenty of volatility for those comfortable with sharp moves in both directions.

References

1. finimize.com, 2. simplywall.st, 3. www.marketbeat.com, 4. finimize.com, 5. ir.medicalpropertiestrust.com, 6. www.marketbeat.com, 7. ir.medicalpropertiestrust.com, 8. ir.medicalpropertiestrust.com, 9. ir.medicalpropertiestrust.com, 10. stockanalysis.com, 11. finviz.com, 12. ir.medicalpropertiestrust.com, 13. ir.medicalpropertiestrust.com, 14. ir.medicalpropertiestrust.com, 15. www.marketbeat.com, 16. ir.medicalpropertiestrust.com, 17. ir.medicalpropertiestrust.com, 18. ir.medicalpropertiestrust.com, 19. ir.medicalpropertiestrust.com, 20. ir.medicalpropertiestrust.com, 21. simplywall.st, 22. ir.medicalpropertiestrust.com, 23. simplywall.st, 24. simplywall.st, 25. simplywall.st, 26. simplywall.st, 27. simplywall.st, 28. finance.yahoo.com, 29. www.marketscreener.com, 30. www.marketbeat.com, 31. www.investing.com, 32. www.nasdaq.com, 33. www.wallstreetzen.com, 34. seekingalpha.com, 35. www.marketbeat.com, 36. www.marketbeat.com, 37. finimize.com, 38. finimize.com, 39. ir.medicalpropertiestrust.com, 40. finimize.com, 41. ir.medicalpropertiestrust.com, 42. simplywall.st, 43. seekingalpha.com, 44. seekingalpha.com, 45. www.marketscreener.com